These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24983591)

  • 21. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.
    Philip NS; Carpenter LL; Tyrka AR; Price LH
    J Psychiatr Pract; 2008 Jan; 14(1):34-44. PubMed ID: 18212601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
    Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
    World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Descriptive analysis of the use of atypical antipsychotics under compassionate-use in a health area in Ferrol (La Coruña, Spain)].
    Santos-García D; Macías M; Casás-Martínez A; Llaneza M; Abella J; Aneiros A; Santos H; Domínguez-Urbistondo G; Salazar-Laya B
    Neurologia; 2010 Jun; 25(5):300-8. PubMed ID: 20643040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism.
    Kampman KM; Pettinati HM; Lynch KG; Whittingham T; Macfadden W; Dackis C; Tirado C; Oslin DW; Sparkman T; O'Brien CP
    J Clin Psychopharmacol; 2007 Aug; 27(4):344-51. PubMed ID: 17632217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting.
    Kasckow JW; Mulchahey JJ; Mohamed S
    J Am Med Dir Assoc; 2004; 5(4):242-8. PubMed ID: 15228634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
    Zedkova I; Dudova I; Urbanek T; Hrdlicka M
    Neuro Endocrinol Lett; 2011; 32(5):667-70. PubMed ID: 22167144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
    McDougle CJ; Stigler KA; Erickson CA; Posey DJ
    J Clin Psychiatry; 2008; 69 Suppl 4():15-20. PubMed ID: 18533764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study.
    Di Fiorino M; Montagnani G; Trespi G; Kasper S
    Int Clin Psychopharmacol; 2014 May; 29(3):166-76. PubMed ID: 24681810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
    Kasper S; Montagnani G; Trespi G; Di Fiorino M
    Int Clin Psychopharmacol; 2015 Jan; 30(1):14-22. PubMed ID: 25356632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
    Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
    Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
    J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
    Bandelow B; Chouinard G; Bobes J; Ahokas A; Eggens I; Liu S; Eriksson H
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):305-20. PubMed ID: 19691907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
    Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
    J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A model of anticholinergic activity of atypical antipsychotic medications.
    Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
    Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
    Erbe S; Gutwinski S; Bschor T
    Psychiatr Prax; 2012 Mar; 39(2):57-63. PubMed ID: 22189902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.